SCHEMBL27172005

SCHEMBL27172005

COC(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1NC1CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 5/20 0.42
YAP1 P46937 1/20 0.40
KDM4E B2RXH2 6/20 0.39
ALDH1A1 P00352 6/20 0.39
ROCK2 O75116 1/20 0.36
DGAT1 O75907 1/20 0.36
USP30 Q70CQ3 1/20 0.35
CHEK1 O14757 1/20 0.35
CHEK2 O96017 1/20 0.35
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ROCK1 Q13464 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
CASP1 P29466 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813648 0.81 HIF1A (0.46) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL20563002 0.81 PDE5A (0.38) HIF1AROCK2DGAT1ROCK1CA1
SCHEMBL25035049 0.80 HIF1A (0.43) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL15567450 0.79 ALDH1A1 (0.53) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL20504704 0.79 KDM4E (0.58) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL209359 0.78 HIF1A (0.43) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL2281668 0.78 ALDH1A1 (0.51) HIF1AKDM4EALDH1A1DGAT1HPGD
SCHEMBL2427372 0.78 LPL (0.44) HIF1AROCK1CA1CA2CA9
SCHEMBL2697552 0.78 CA1 (0.53) HIF1ADGAT1CA1CA2CA9
SCHEMBL31258763 0.78 CA1 (0.53) HIF1ADGAT1CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-07-25 US disclosed
EP-4337660-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS Bristol-Myers Squibb Company (US) 2024-03-20 EP disclosed
CN-117597345-A Heterocyclic derivatives as CaMKK2 inhibitors 百时美施贵宝公司 2024-02-23 CN disclosed
WO-2022240826-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2022-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS CAMKK2, CAMKK1, CAMK1 HIF1A 1068/4885YAP1 993/4885KDM4E 2232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.